Arbutus Biopharma Announces 46 Million Share Buyback to Boost Value

Key Facts

1Arbutus Biopharma announced a 46 million share buyback program to enhance per-share value.

2The company is leveraging a $179.1M settlement from Moderna to fund its chronic hepatitis B (HBV) cure research.

Arbutus Biopharma announced a 46 million share buyback program to enhance per-share value for its investors. Seeking Alpha reported that the company is leveraging a $179.1 million financial settlement from Moderna to fund its ongoing research into a cure for chronic hepatitis B.

The company aims to provide a stable financial runway for Phase 2b/3 clinical trials of its drug candidate, Imdusiran, using the influx of cash. ABUS closed at $4.29 on October 7, 2026, while MRNA closed at $196.48 on the same date.